Liquidia (NASDAQ:LQDA) Rating Lowered to Hold at Zacks Research

Liquidia (NASDAQ:LQDA) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Thursday,Zacks.com reports.

LQDA has been the topic of a number of other reports. Wall Street Zen lowered shares of Liquidia from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 27th. Piper Sandler set a $129.00 target price on shares of Liquidia in a research note on Friday, July 24th. Raymond James Financial reiterated a “strong-buy” rating and set a $106.00 target price on shares of Liquidia in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research note on Friday, July 17th. Finally, Wells Fargo & Company boosted their price target on Liquidia from $62.00 to $108.00 and gave the company an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $98.08.

Liquidia Stock Performance

Shares of Liquidia stock opened at $74.44 on Thursday. The stock’s fifty day simple moving average is $78.67 and its 200 day simple moving average is $55.13. The company has a current ratio of 2.31, a quick ratio of 2.03 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $6.62 billion, a PE ratio of 54.34 and a beta of 0.58. Liquidia has a 12 month low of $21.15 and a 12 month high of $93.61.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The business had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same quarter last year, the company earned ($0.49) earnings per share. The firm’s revenue was up 1842.1% compared to the same quarter last year. On average, research analysts predict that Liquidia will post 2.74 EPS for the current year.

Insider Activity

In other news, Director Stephen M. Bloch sold 242,269 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $70.43, for a total transaction of $17,063,005.67. Following the completion of the sale, the director owned 1,176,184 shares in the company, valued at approximately $82,838,639.12. This trade represents a 17.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Paul B. Manning sold 200,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $63.91, for a total value of $12,782,000.00. Following the sale, the director owned 716,311 shares of the company’s stock, valued at approximately $45,779,436.01. This represents a 21.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 1,756,861 shares of company stock worth $122,981,112 over the last three months. Insiders own 25.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in LQDA. Northwestern Mutual Wealth Management Co. bought a new position in shares of Liquidia during the fourth quarter worth approximately $25,000. NewEdge Advisors LLC bought a new stake in Liquidia during the second quarter worth about $25,000. Covestor Ltd grew its stake in Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares in the last quarter. Tower Research Capital LLC TRC grew its stake in Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after buying an additional 4,927 shares in the last quarter. Finally, Globeflex Capital L P bought a new position in Liquidia in the 2nd quarter valued at about $175,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales drove second-quarter revenue to $171.68 million, exceeding the $168.48 million consensus estimate, while revenue increased more than 1,800% year over year. Management also highlighted rising demand for the inhaled lung-disease treatment. LQDA Q2 Earnings Top
• Positive Sentiment: Liquidia is targeting more than $1 billion in 2027 net revenue as YUTREPIA gains market share and helps fund a broader inhaled-treprostinil pipeline, providing investors with a significant long-term growth narrative. LQDA Earnings Call Highlights
• Positive Sentiment: Bank of America raised its price target from $79 to $92, while BTIG Research and Needham indicated further appreciation potential. These targets support the bullish case, although Bank of America retained a neutral rating. Bank of America Price Target
• Neutral Sentiment: Lifesci Capital initiated or maintained a Market Perform view, reflecting more balanced expectations despite the company’s strong commercial momentum. Lifesci Capital Rating
• Negative Sentiment: Second-quarter adjusted earnings of $0.74 per share narrowly missed the $0.76 consensus estimate. The results triggered a negative reaction despite the revenue beat, particularly after LQDA had already risen sharply this year. Liquidia Shares Gap Down
• Negative Sentiment: HC Wainwright lowered its third-quarter 2026 EPS forecast to $1.01 from $1.15, adding pressure to near-term expectations. With a reported price-to-earnings ratio above 54, investors may be particularly sensitive to estimate reductions. HC Wainwright Estimate Revision

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).